Ligation

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Retrieved on: 
Monday, February 26, 2024
Bias, DNA, Ligation, MBA, NGS, Roche, Fine chemical

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.
  • This deal supersedes the prior exclusive license on the EvoT4™ DNA ligase.
  • We are excited to collaborate again with Roche on this novel, dsDNA ligase.
  • Compared to wild-type enzyme, the newly engineered dsDNA ligase is developed to higher ligation efficiency in shorter reaction times and higher library yields and complexity, with minimal substrate sequence bias.

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Sunday, November 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, Trial of the century, NSCLC, B cell, CD8, NKG2C, SITC, LILRB1, Ligation, CD39, NK, Cancer, Annual general meeting, Tumor microenvironment, Safety, Lymphocyte, TME, Patient, MPE, Vaccine, Medical imaging

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.
  • CD39-targeted TGFβ “trap” is thus more likely to effectively inhibit tumor progression.
  • Our NKG2A/NKG2C dual targeting antibody ES015-2 can inhibit NKG2A function yet promoting NKG2C action, leading to superior anti-tumor response.
  • ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells.

Integrated DNA Technologies Reveals Launch of xGen™ Products for Ultima Genomics®

Retrieved on: 
Wednesday, September 27, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Learning, DNA, XGen Studios, Genomics, NGS, Integrated DNA Technologies, Ligation, Multimedia, RNA, Manager, Chemistry, IDT, Ultima, WGS, Small Business Saturday, Integration, PCR, Fine chemical, Antibiotics, Birth control, Paint

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.

Key Points: 
  • With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.
  • The products are designed to minimize sequence errors from PCR or sequencing that might impact demultiplexing.
  • xGen HybCap Adapters for Ultima Genomics—full-length adapters for library construction prior to hybridization capture, using TA-ligation workflows for incorporating sample indexing during the ligation step.
  • xGen HybCap Lib Amp Primers for Ultima Genomics—premixed PCR primers used to increase yield for sequencing libraries post-hybridization capture.

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

Retrieved on: 
Tuesday, September 12, 2023
Infection, Biologics license application, KOL, Extremities, Surgeon, File, Amputation, Conference call, Internet, Ligation, Clinical trial, Trauma, Sale, Saphenous, Regenerative Medicine Advanced Therapy, Food and Drug Administration Amendments Act of 2007, Patient, Standard of care, Risk, HUMA, Injury, Peripheral artery disease, FDA, HAV, BLA, Conference, Food, Vaccine, Pharmaceutical industry

DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) --  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. The single-arm clinical trial was a success and showed that the HAV in this study had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application (BLA) for the treatment of vascular trauma with the Food and Drug Administration (FDA) during the 4th quarter of 2023.

Key Points: 
  • ET today -
    DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) --  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
  • Humacyte plans to file a Biologics License Application (BLA) for the treatment of vascular trauma with the Food and Drug Administration (FDA) during the 4th quarter of 2023.
  • Patients enrolled in the study did not have the standard of care, saphenous vein, available to use as a bypass graft.
  • Human Acellular Vessel (HAV) for Vascular Trauma Repair: Top Line Phase 2/3 V005 Results and KOL Perspectives

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         

Retrieved on: 
Friday, July 28, 2023
DED, Gabapentin, Investigational New Drug, Principal investigator, Ligation, Clinical trial, Quality of life, Telecanthus, Professor, Tufts Medical Center, MD, Patient, NCP, Risk, University of Texas at Dallas academic programs, Nonsteroidal anti-inflammatory drug, Steroid, Mouse, Principal, FDA, IND, Safety, Pharmaceutical industry, Research

NCP is a debilitating condition characterized by chronic and severe eye discomfort, leading to decreased quality of life for affected individuals.

Key Points: 
  • NCP is a debilitating condition characterized by chronic and severe eye discomfort, leading to decreased quality of life for affected individuals.
  • OK-101, a novel and investigational therapeutic developed by OKYO Pharma, offers a promising solution to alleviate the symptoms associated with NCP.
  • This collaborative effort is focused on evaluating OK-101 as a potential non-opioid analgesic to reduce neuropathic corneal pain, a major unmet medical need.
  • Further details regarding the specifics of the trial are posted on the clinicaltrials.gov public website (clinicaltrials.gov Identifier: NCT05759208 or https://clinicaltrials.gov/ct2/results?term=Okyo&cond=Dry+Eye+Syndromes ).

Visualizing Quantitative Market Trends in Wound Care Management: Key Growth Drivers for Global Ligating Clips Market Unveiled in New Report - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023
Surgery, Health, Medical Supplies, ASP, Internet, COVID-19, Ligation, Market access, CMO, Strategic planning, Blood, SWOT, Hemostasis, Patient, Investment, Patient safety, Reading, SWOT analysis, Region, Epidemiology, LIBOR market model, Procedure, Country, Retail, Birth control, Health care, Risk management

This report was built to visualize quantitative market trends within Wound Care Management therapeutic area.

Key Points: 
  • This report was built to visualize quantitative market trends within Wound Care Management therapeutic area.
  • Ligating clips are broadly divided into: Titanium ligating clips and Polymer ligating clips.
  • Key Inclusions of the market model are:
    Currently marketed Ligating Clips and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.

Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026

Retrieved on: 
Thursday, July 20, 2023
Workforce, DNA, EPI, Probability, MBBS, Therapy, Exocrine pancreatic insufficiency, Bank statement, RNA, Ligation, Enzyme, Medication, Doctor of Philosophy, Messenger, Pharmaceutical manufacturing, Small RNA, RNA interference, Metabolism, Patient, ECO, Administration, Engineering, Growth, Conference, Fine chemical, Risk management, Pharmaceutical industry, Cryptocurrency, Protalix BioTherapeutics, Codexis

REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that, in alignment with its previously announced strategy to focus resources on programs with the strongest probability of creating significant value in the near-term and beyond, the Company intends to prioritize the advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and its highly complementary Pharmaceutical Manufacturing business. As part of this enhanced strategic focus, the Company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%. Codexis had $92.1 million in cash and cash equivalents as of June 30, 2023, and with these changes expects that this balance will be sufficient to fund its planned operations to mid-2026, providing the Company the opportunity to deliver on critical milestones related to its ECO Synthesis™ platform.

Key Points: 
  • As part of this enhanced strategic focus, the Company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%.
  • We believe Codexis is uniquely positioned to design and bring to market an enzymatic solution that addresses this challenge.
  • As of June 30, 2023, the Company had cash and cash equivalents of $92.1 million.
  • As of June 30, 2023, the Company had an estimated $92.1 million in cash and cash equivalents.

China Precision Medicine Business Opportunities Databook 2023: Focus on Mepolizumab, Osimertinib, Aripiprazole Lauroxil, & Alectinib - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 13, 2023
Health, Pharmaceutical, Cloud, Molecule, SRL Diagnostics, Clinical Laboratory, Oncology, Biotechnology, Drug discovery, Health care, Personalized medicine, Bioinformatics, European Technology Platform Nanomedicine, CNS, Medication, Data wrangling, Ligation, Administration, Application, Nanopore sequencing, Ion semiconductor sequencing, Others, Update, Medicine, Route of administration, Oral, Injection (medicine), Therapy, Diagnosis, Infection, Semiconductor, Fine chemical, Marketing, Medical device, Pet industry

The "China Precision Medicine Business Opportunities Databook - Q2 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Precision Medicine Business Opportunities Databook - Q2 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • China's precision medicine market size is expected to record a CAGR of 13% during 2023-2027 to reach US$6.403 billion by 2027, increasing from US$3.92 billion in 2023.
  • In-depth understanding of precision medicine market dynamics: Understand market opportunity, industry dynamics, key trends, and drivers across different market segments and sub-segments of the industry increate China.
  • 1 China Precision Medicine Market Size and Forecast, 2018-2027
    2 China Precision Medicine Market Share by Category, 2018-2027
    2.1 China Precision Medicine Market Size by Diagnosis, 2018-2027
    2.2 China Precision Medicine Market Size by Therapeutics, 2018-2027
    2.3 China Precision Medicine Market Size by Others, 2018-2027
    3 China Precision Medicine Market Share by Technology Platforms, 2018-2027
    3.1 Precision Medicine Market Size by Cloud-Based Platform, 2018-2027
    3.2 Precision Medicine Market Size by On-Premise Platform, 2018-2027
    4 China Precision Medicine Market Share by Technology, 2018-2027
    4.1 Precision Medicine Market Size by Bioinformatics, 2018-2027
    4.2 Precision Medicine Market Size by Big Data Analytics, 2018-2027
    4.3 Precision Medicine Market Size by Drug Discovery, 2018-2027
    4.4 Precision Medicine Market Size by Companion Diagnostics, 2018-2027
    4.5 Precision Medicine Market Size by Gene Sequencing, 2018-2027
    4.6 Precision Medicine Market Size by Others, 2018-2027
    5 China Precision Medicine Market Share by Gene Sequencing, 2018-2027
    5.1 Precision Medicine Market Size by Chain Termination Sequencing, 2018-2027
    5.2 Precision Medicine Market Size by Nanopore Sequencing, 2018-2027
    5.3 Precision Medicine Market Size by Sequencing by Ligation, 2018-2027
    5.4 Precision Medicine Market Size by Pyrosequencing, 2018-2027
    5.5 Precision Medicine Market Size by Ion Semiconductor Sequencing, 2018-2027
    5.6 Precision Medicine Market Size by Single Molecule Real Time Sequencing, 2018-2027
    5.7 Precision Medicine Market Size by Sequencing by Synthesis, 2018-2027
    6 China Precision Medicine Market Share by Drugs, 2018-2027
    6.1 Precision Medicine Market Size by Mepolizumab, 2018-2027
    6.2 Precision Medicine Market Size by Osimertinib, 2018-2027
    6.3 Precision Medicine Market Size by Aripiprazole Lauroxil, 2018-2027
    6.4 Precision Medicine Market Size by Alectinib, 2018-2027
    6.5 Precision Medicine Market Size by Others, 2018-2027
    7 China Precision Medicine Market Share by Route of Administration, 2018-2027
    7.1 Precision Medicine Market Size by Injectable, 2018-2027
    7.2 Precision Medicine Market Size by Oral, 2018-2027
    7.3 Precision Medicine Market Size by Others, 2018-2027
    8 China Precision Medicine Market Share by Application, 2018-2027
    8.1 Precision Medicine Market Size by Oncology, 2018-2027
    8.2 Precision Medicine Market Size by CNS, 2018-2027
    8.3 Precision Medicine Market Size by Cardiovascular, 2018-2027
    8.4 Precision Medicine Market Size by Infectious Diseases, 2018-2027
    8.5 Precision Medicine Market Size by Others, 2018-2027
    9 China Precision Medicine Market Share by End User, 2018-2027
    9.1 Precision Medicine Market Size by Pharmaceuticals and Biotechnology Companies, 2018-2027
    9.2 Precision Medicine Market Size by Diagnostics Companies, 2018-2027
    9.3 Precision Medicine Market Size by Healthcare IT Specialists/Big Data Companies, 2018-2027
    9.4 Precision Medicine Market Size by Clinical Laboratories, 2018-2027

Global DNA Digital Data Storage Market Outlook 2023-2035: Rising Investment to Enhance Data Storage Capacity to Bolster Growth

Retrieved on: 
Thursday, June 22, 2023
Cloud, Market value, Segment, USD, Ligation, Ion semiconductor sequencing, Quality control, Nanopore sequencing, Research, Cryptocurrency, Speciality chemicals

Synthesis, Market Value (USD million), CAGR, 2022-2035F

Key Points: 
  • Synthesis, Market Value (USD million), CAGR, 2022-2035F
    19.3.1.2.
  • Ion Semiconductor, Market Value (USD million), CAGR, 2022-2035F
    19.3.1.3.
  • Chain Termination, Market Value (USD million), CAGR, 2022-2035F
    19.3.1.4.
  • Nanopore Sequencing, Market Value (USD million), CAGR, 2022-2035F
    19.3.2.1.

Global Microbiome Sequencing Services Market Report 2023: High Cost of Advanced Infrastructure for Sequencing Fuels the Sector

Retrieved on: 
Tuesday, May 30, 2023
SBS, Therapy, SCFA, Nucleotide, Ligation, MEA, Research, Amplicon, Nanopore sequencing, Microbiota, SBL, Real-time, Data analysis, Growth, Health, Whole genome sequencing, Dentistry, Disease, Fine chemical, Antibiotics

DUBLIN, May 29, 2023 /PRNewswire/ -- The "Global Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome Sequencing), Technology (Sequencing by Synthesis, Nanopore Sequencing), End User - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 29, 2023 /PRNewswire/ -- The "Global Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome Sequencing), Technology (Sequencing by Synthesis, Nanopore Sequencing), End User - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Microbiome sequencing is expanding its applications beyond research and is increasingly being utilized in therapeutics development, including the study of the skin microbiome and oral microbiome sequencing.
  • Based on service, the microbiome sequencing services market is segmented into sample preparation services, sequencing and library preparation services, and data analysis services.
  • Based on technology, the global microbiome sequencing services market is segmented into sequencing by synthesis (SBS), sequencing by ligation (SBL), nanopore sequencing, and other technologies.